3-methyl-1-morpholinobutan-1-one | 22342-12-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 恶嗪烷类
• 英文名称: 3-methyl-1-morpholinobutan-1-one
• 英文别名: Isovaleriansaeure-morpholid；4-(3-methyl-butyryl)-morpholine；3-Methyl-1-morpholin-4-ylbutan-1-one
• CAS: 22342-12-7
• 化学式: C₉H₁₇NO₂
• mdl: MFCD00460292
• 分子量: 171.239
• InChiKey: MEJSGHHRMQZWHL-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.6
• 重原子数：
  12
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.888
• 拓扑面积：
  29.5
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  3-methyl-1-morpholinobutan-1-one 在 sodium hydroxide 、 三氯氧磷 作用下， 以 水 为溶剂， 反应 2.25h， 生成 1-Methyl-3-propan-2-ylquinolin-4-one
  参考文献：
  名称：

  从甲虫中一步合成喹啉鎓盐和4-喹诺酮类化合物的新方法

  摘要：

  N-甲基甲酰苯胺在将POCl 3下进行反应容易地在80℃下用alkanoamides（RCH 2 CONR” 2），得到良好的收率3-R-4-chloroquinolinium盐。芳基酰胺以其维斯迈尔盐形式反应，而链烷酰胺以α-氯烯胺形式反应。通过碱处理容易获得高产率的4-喹诺酮。

  DOI：

  10.1016/s0040-4039(00)73654-9
• 作为产物：
  描述：

  异戊酸 、 4-乙酰基吗啉 生成 3-methyl-1-morpholinobutan-1-one
  参考文献：
  名称：

  Synthesis of piperidides and morpholides of organic acids by reactions of transamidation and study of their repellent activity

  摘要：

  DOI：

  10.1007/bf00760737

文献信息

• APOPTOSIS SIGNAL-REGULATING KINASE 1 INHIBITORS AND METHODS OF USE THEREOF
  申请人：Enanta Pharmaceuticals, Inc.

  公开号：US20200157095A1

  公开（公告）日：2020-05-21

  The present invention discloses compounds of Formula (I), and pharmaceutically acceptable salts and esters thereof: which inhibit the Apoptosis signal-regulating kinase 1 (ASK-1), which associated with autoimmune disorders, neurodegenerative disorders, inflammatory diseases, chronic kidney disease, cardiovascular disease. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from ASK-1 related disease. The invention also relates to methods of treating an ASK-1 related disease in a subject by administering a pharmaceutical composition comprising the compounds of the present invention. The present invention specifically relates to methods of treating ASK-1 associated with hepatic steatosis, including non-alcoholic fatty liver disease (NAFLD) and non-alcohol steatohepatitis disease (NASH).

  本发明公开了化合物的结构式(I)，以及其药学上可接受的盐和酯： 这些化合物抑制凋亡信号调节激酶1（ASK-1），与自身免疫性疾病、神经退行性疾病、炎症性疾病、慢性肾脏疾病、心血管疾病相关。本发明还涉及包含上述化合物的药物组合物，用于治疗患有ASK-1相关疾病的受试者。该发明还涉及通过给予包含本发明化合物的药物组合物来治疗受试者的ASK-1相关疾病的方法。本发明具体涉及治疗与肝脂肪变性相关的ASK-1的方法，包括非酒精性脂肪肝病（NAFLD）和非酒精性脂肪性肝炎病（NASH）。
• Catalytic Transamidation Reactions Compatible with Tertiary Amide Metathesis under Ambient Conditions
  作者：Nickeisha A. Stephenson、Jiang Zhu、Samuel H. Gellman、Shannon S. Stahl

  DOI：10.1021/ja8094262

  日期：2009.7.29

  present study reveals that simple zirconium- and hafnium-amido complexes are highly efficient catalysts for equilibrium-controlled transamidation reactions between secondary amines and tertiary amides. In a number of cases, transamidation proceeds rapidly at room temperature. We find that these new catalysts are sufficiently active to promote the metathesis of tertiary amides, which arises from successive

  甲酰胺的碳氮键在大多数条件下都非常稳定。本研究表明，简单的锆和铪酰胺配合物是仲胺和叔酰胺之间平衡控制的转酰胺反应的高效催化剂。在许多情况下，转酰胺作用在室温下进行得很快。我们发现这些新催化剂的活性足以促进叔酰胺的复分解，这是由连续的转酰胺循环产生的。我们观察到的催化活性是前所未有的，代表了朝着用羧酰胺进行平衡控制反应的长期目标迈出的重要一步。
• TYK2 INHIBITORS AND USES THEREOF
  申请人：Nimbus Lakshmi, Inc.

  公开号：US20200131201A1

  公开（公告）日：2020-04-30

  The present invention provides compounds, compositions thereof, and methods of using the same for the inhibition of TYK2, and the treatment of TYK2-mediated disorders.

  本发明提供了化合物、其组合物以及使用它们来抑制TYK2并治疗TYK2介导的疾病的方法。
• N2-(2-METHOXYPHENYL)PYRIMIDINE DERIVATIVE, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL COMPOSITION FOR CANCER PREVENTION OR TREATMENT CONTAINING SAME AS ACTIVE INGREDIENT
  申请人：KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY

  公开号：US20180111905A1

  公开（公告）日：2018-04-26

  The present invention relates to a N2-(2-methoxyphenyl)pyrimidine derivative, a preparation method thereof, and a pharmaceutical composition for the prevention or treatment of cancer comprising the same as an active ingredient. The N2-(2-methoxyphenyl)pyrimidine derivative, the optical isomer thereof, or the pharmaceutically acceptable salt thereof of the present invention is very effective in suppressing anaplastic lymphoma kinase (ALK) activity and as a result it can improve the effectiveness of treatment on cancer cells having anaplastic lymphoma kinase (ALK) fusion proteins such as EML4-ALK and NPM-ALK, so that it can be effectively used as a pharmaceutical composition for preventing or treating cancer.

  本发明涉及一种N2-(2-甲氧基苯基)嘧啶衍生物，其制备方法，以及包含其作为活性成分的用于预防或治疗癌症的药物组合物。本发明的N2-(2-甲氧基苯基)嘧啶衍生物，其光学异构体，或其药学上可接受的盐对抑制间变性淋巴瘤激酶（ALK）活性非常有效，从而可以提高对具有间变性淋巴瘤激酶（ALK）融合蛋白如EML4-ALK和NPM-ALK的癌细胞的治疗效果，因此可以有效地用作预防或治疗癌症的药物组合物。
• NOVEL INDOLE DERIVATIVES AND THEIR USE IN NEURODEGENERATIVE DISEASES
  申请人：Merck Patent GmbH

  公开号：US20160168090A1

  公开（公告）日：2016-06-16

  The present invention relates to indole compounds, and pharmaceutically acceptable compositions thereof, useful as antagonists of P2X7, and for the treatment of P2X7-related disorders.

  本发明涉及吲哚化合物及其药用可接受的组合物，用作P2X7拮抗剂，用于治疗与P2X7相关的疾病。